Advocates hold a vigil outside of Eli Lilly offices in New York City on September 5, 2019.
Top Pharma Giants Rake in Huge Profits and Reward Investors While Hiking Drug Prices: Analysis
"Seniors and families already struggling to afford lifesaving medicines are told to brace for further price hikes by the same industry that saw its profits and shareholder rewards skyrocket by billions in a year."
An analysis published Tuesday shows that the five largest pharmaceutical companies in the United States raked in combined earnings of $82 billion last year and rewarded investors with billions of dollars in dividends and stock buybacks—all while hiking prices for prescription drugs and fighting federal efforts to curb costs.
The new analysis by the progressive watchdog group Accountable.US finds that Eli Lilly, Johnson & Johnson, Merck, AbbVie, and Pfizer increased their combined share repurchases and dividends by $4.4 billion and $2.5 billion respectively in 2022 as their profits grew by nearly $9 billion compared to 2021.
Last year, pharmaceutical companies raised the prices of more than 1,100 medicines, according to a tally by Patients for Affordable Drugs.
At the start of 2023, drugmakers hiked the prices of at least 350 medicines. While Eli Lilly and other insulin makers announced plans to cut the prices of their most commonly used insulin products earlier this year, they have benefited from decades of harmful price gouging.
"Seniors and families already struggling to afford lifesaving medicines are told to brace for further price hikes by the same industry that saw its profits and shareholder rewards skyrocket by billions in a year," Liz Zelnick, director of Accountable.US' Economic Security and Corporate Power program, said in a statement Tuesday. "It only adds up to corporate greed."
"Pharma executives' claims that research and development expenses drive costs remain unconvincing," Zelnick added, "when those costs are often eclipsed by billions of dollars in handouts to a small group of wealthy investors."
The analysis comes as the pharmaceutical industry is suing the Biden administration over a 2022 law that gives Medicare the authority to negotiate the prices of a small number of high-cost medications directly with drugmakers.
Merck—which, according to Accountable.US, saw its profits rise to over $14.5 billion last year—launched the industry's widely expected legal attack on the Inflation Reduction Act (IRA) provisions last month with a suit against the Health and Human Services Department.
Pharmaceutical Research and Manufacturers of America (PhRMA) joined the fight two weeks later. Bristol Myers Squibb, Astellas Pharma, Johnson & Johnson, and the U.S. Chamber of Commerce have also sued the Biden administration over the drug price negotiation provisions.
"The suits make similar and overlapping claims that the drug pricing provisions are unconstitutional," The New York Times reported Monday. "They are scattered in federal courts around the country—a tactic that experts say gives the industry a better chance of obtaining conflicting rulings that will put the legal challenges on a fast track to a business-friendly Supreme Court."
Zelnick argued Tuesday that drug companies' aggressive campaign against the drug price negotiations with Medicare "is all about preserving their industry's corporate profiteering strategy, which has clearly been immune to repeated interest rate hikes from the Fed."
Accountable.US' analysis notes that "in the years leading up to the passage of the IRA," PhRMA spent "nearly $70 million lobbying against efforts to allow Medicare to negotiate the prices of prescription drugs and other measures to lower drug prices."
Urgent. It's never been this bad.
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission from the outset was simple. To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It’s never been this bad out there. And it’s never been this hard to keep us going. At the very moment Common Dreams is most needed and doing some of its best and most important work, the threats we face are intensifying. Right now, with just four days to go in our Spring Campaign, we are not even halfway to our goal. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Can you make a gift right now to make sure Common Dreams not only survives but thrives? There is no backup plan or rainy day fund. There is only you. —Craig Brown, Co-founder |
An analysis published Tuesday shows that the five largest pharmaceutical companies in the United States raked in combined earnings of $82 billion last year and rewarded investors with billions of dollars in dividends and stock buybacks—all while hiking prices for prescription drugs and fighting federal efforts to curb costs.
The new analysis by the progressive watchdog group Accountable.US finds that Eli Lilly, Johnson & Johnson, Merck, AbbVie, and Pfizer increased their combined share repurchases and dividends by $4.4 billion and $2.5 billion respectively in 2022 as their profits grew by nearly $9 billion compared to 2021.
Last year, pharmaceutical companies raised the prices of more than 1,100 medicines, according to a tally by Patients for Affordable Drugs.
At the start of 2023, drugmakers hiked the prices of at least 350 medicines. While Eli Lilly and other insulin makers announced plans to cut the prices of their most commonly used insulin products earlier this year, they have benefited from decades of harmful price gouging.
"Seniors and families already struggling to afford lifesaving medicines are told to brace for further price hikes by the same industry that saw its profits and shareholder rewards skyrocket by billions in a year," Liz Zelnick, director of Accountable.US' Economic Security and Corporate Power program, said in a statement Tuesday. "It only adds up to corporate greed."
"Pharma executives' claims that research and development expenses drive costs remain unconvincing," Zelnick added, "when those costs are often eclipsed by billions of dollars in handouts to a small group of wealthy investors."
The analysis comes as the pharmaceutical industry is suing the Biden administration over a 2022 law that gives Medicare the authority to negotiate the prices of a small number of high-cost medications directly with drugmakers.
Merck—which, according to Accountable.US, saw its profits rise to over $14.5 billion last year—launched the industry's widely expected legal attack on the Inflation Reduction Act (IRA) provisions last month with a suit against the Health and Human Services Department.
Pharmaceutical Research and Manufacturers of America (PhRMA) joined the fight two weeks later. Bristol Myers Squibb, Astellas Pharma, Johnson & Johnson, and the U.S. Chamber of Commerce have also sued the Biden administration over the drug price negotiation provisions.
"The suits make similar and overlapping claims that the drug pricing provisions are unconstitutional," The New York Times reported Monday. "They are scattered in federal courts around the country—a tactic that experts say gives the industry a better chance of obtaining conflicting rulings that will put the legal challenges on a fast track to a business-friendly Supreme Court."
Zelnick argued Tuesday that drug companies' aggressive campaign against the drug price negotiations with Medicare "is all about preserving their industry's corporate profiteering strategy, which has clearly been immune to repeated interest rate hikes from the Fed."
Accountable.US' analysis notes that "in the years leading up to the passage of the IRA," PhRMA spent "nearly $70 million lobbying against efforts to allow Medicare to negotiate the prices of prescription drugs and other measures to lower drug prices."
An analysis published Tuesday shows that the five largest pharmaceutical companies in the United States raked in combined earnings of $82 billion last year and rewarded investors with billions of dollars in dividends and stock buybacks—all while hiking prices for prescription drugs and fighting federal efforts to curb costs.
The new analysis by the progressive watchdog group Accountable.US finds that Eli Lilly, Johnson & Johnson, Merck, AbbVie, and Pfizer increased their combined share repurchases and dividends by $4.4 billion and $2.5 billion respectively in 2022 as their profits grew by nearly $9 billion compared to 2021.
Last year, pharmaceutical companies raised the prices of more than 1,100 medicines, according to a tally by Patients for Affordable Drugs.
At the start of 2023, drugmakers hiked the prices of at least 350 medicines. While Eli Lilly and other insulin makers announced plans to cut the prices of their most commonly used insulin products earlier this year, they have benefited from decades of harmful price gouging.
"Seniors and families already struggling to afford lifesaving medicines are told to brace for further price hikes by the same industry that saw its profits and shareholder rewards skyrocket by billions in a year," Liz Zelnick, director of Accountable.US' Economic Security and Corporate Power program, said in a statement Tuesday. "It only adds up to corporate greed."
"Pharma executives' claims that research and development expenses drive costs remain unconvincing," Zelnick added, "when those costs are often eclipsed by billions of dollars in handouts to a small group of wealthy investors."
The analysis comes as the pharmaceutical industry is suing the Biden administration over a 2022 law that gives Medicare the authority to negotiate the prices of a small number of high-cost medications directly with drugmakers.
Merck—which, according to Accountable.US, saw its profits rise to over $14.5 billion last year—launched the industry's widely expected legal attack on the Inflation Reduction Act (IRA) provisions last month with a suit against the Health and Human Services Department.
Pharmaceutical Research and Manufacturers of America (PhRMA) joined the fight two weeks later. Bristol Myers Squibb, Astellas Pharma, Johnson & Johnson, and the U.S. Chamber of Commerce have also sued the Biden administration over the drug price negotiation provisions.
"The suits make similar and overlapping claims that the drug pricing provisions are unconstitutional," The New York Times reported Monday. "They are scattered in federal courts around the country—a tactic that experts say gives the industry a better chance of obtaining conflicting rulings that will put the legal challenges on a fast track to a business-friendly Supreme Court."
Zelnick argued Tuesday that drug companies' aggressive campaign against the drug price negotiations with Medicare "is all about preserving their industry's corporate profiteering strategy, which has clearly been immune to repeated interest rate hikes from the Fed."
Accountable.US' analysis notes that "in the years leading up to the passage of the IRA," PhRMA spent "nearly $70 million lobbying against efforts to allow Medicare to negotiate the prices of prescription drugs and other measures to lower drug prices."